Lv1
100 积分 2024-12-31 加入
Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial
10小时前
已完结
Unleashing precision: a review of targeted approaches in pleural mesothelioma
1个月前
已关闭
BL-B01D1, a first-in-class EGFR–HER3 bispecific antibody–drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study
1个月前
已完结
Assessing safety concerns of interstitial lung disease associated with antibody-drug conjugates: a real-world pharmacovigilance evaluation of the FDA adverse event reporting system
1个月前
已完结
Clinical best practices in interdisciplinary management of human epidermal growth factor receptor 2 antibody‐drug conjugates–induced interstitial lung disease/pneumonitis: An expert consensus in China
1个月前
已完结
Interstitial lung diseases
1个月前
已完结
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
2个月前
已完结
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
2个月前
已完结
Non-small-cell lung cancer
2个月前
已完结
皖公网安备34019202002308
